Asthma Drugs Market (By Medication: Quick Relief Medications, Long-term Control Medications, Others; By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections, and Sprays and Powders; By Organization Type: Public, Private; By Application: Pediatric, Adults, Adolescent) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2024 - 2033

The global asthma drugs market size was valued at USD 24.45 billion in 2023 and is projected to surpass around USD 40.17 billion by 2033, registering a CAGR of 5.09% over the forecast period of 2024 to 2033.

Asthma Drugs Market Key Takeaways

• North America led the global market with the highest market share of 49.56% in 2023.
• By Medication, the quick relief medications segment has held the largest market share in 2023.
• By Mode of Administration, the inhalers segment captured the biggest revenue share in 2023.
• By Organization Type, the public segment is estimated to hold the highest market share in 2023.
• By Application, the adults segment registered the maximum market share in 2023.

Asthma Drugs Market Overview

The asthma drugs market encompasses a vital segment of the pharmaceutical industry, dedicated to addressing the treatment needs of individuals suffering from asthma, a chronic respiratory condition characterized by airway inflammation and constriction. With millions affected globally, this market plays a crucial role in providing medications aimed at managing and alleviating asthma symptoms, thereby improving patients' quality of life. The market offers a diverse range of medications categorized into controller drugs, which target inflammation to prevent symptoms, and reliever drugs, which provide immediate relief during asthma attacks. Over the years, advancements in drug research and development have led to the introduction of innovative formulations and delivery systems, enhancing efficacy and patient compliance. Factors such as increasing asthma prevalence, fueled by environmental factors and lifestyle changes, contribute to market growth. Moreover, the rising demand for personalized medicine approaches tailored to individual patient needs further drives innovation in this sector. With ongoing research and development efforts, coupled with a growing patient population, the asthma drugs market continues to evolve, offering opportunities for pharmaceutical companies to innovate and improve treatment options for asthma sufferers.

Asthma Drugs Market Growth Factors

The growth of the asthma drugs market is driven by several key factors. Firstly, the rising prevalence of asthma worldwide, attributed to factors like increasing pollution levels, urbanization, and lifestyle changes, fuels the demand for effective medications. Additionally, advancements in drug research and development, leading to the introduction of novel formulations with improved efficacy and reduced side effects, contribute to market expansion. Moreover, the growing emphasis on personalized medicine approaches, tailoring treatment plans to individual patient needs and characteristics, further drives market growth. Furthermore, the development of innovative drug delivery systems enhances the convenience and effectiveness of asthma medications, attracting both patients and healthcare providers. Overall, these factors collectively propel the growth of the asthma drugs market, creating opportunities for pharmaceutical companies to innovate and meet the evolving needs of patients with asthma.

Asthma Drugs Market Report Scope

Future of Global Asthma Drugs Market

Foremost players of the global asthma drugs industry are focusing on the strategic partnerships similar acquisitions, mergers in order to enhance their position in the global market and to get the comparative edge. Further companies are launching advanced products in order to fulfill the customized demands of the end-users. These trends are anticipated to continue and will fuel growth of target market over the forecast time-frame. Growing use of asthma drugs for the effective treatment for COVID-19 is key trend witnessed in the target market, this trend is anticipated to continue and will boost growth of this industry in the near future. Asthma drugs that are used to help prevent the symptoms of asthma, are being touted as the silver bullet for COVID-19. Asthma drugs reduce severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. As the COVID-19 and asthma are respiratory illnesses, most of the end-user is also using asthma inhalers for treatment of COVID-19.

Asthma Drugs Market Trends

The Short-acting Beta-2 Agonists Segment is Expected to Witness Significant Growth Over the Forecast Period

Short-acting beta-2 agonists are bronchodilators, rapidly relaxing airway smooth muscle cells to relieve bronchoconstriction and improve airflow. They are the first-line treatments for managing acute asthma symptoms such as wheezing, shortness of breath, chest tightness, and exercise-induced bronchoconstriction (EIB). Most used short-acting beta-2 agonists include albuterol (salbutamol) and terbutaline, primarily delivered via metered-dose inhalers (MDIs) or nebulizers.

Reliever therapy plays a critical role in effective medications in managing sudden asthma symptoms and preventing severe asthma attacks. Short-acting beta-agonists (SABAs) are a prominent choice for quick relief due to their rapid onset of action. The portability and user-friendliness of metered-dose inhalers (MDIs) make them an ideal solution for on-the-spot symptom management. This characteristic is especially attractive to patients who struggle to adhere to the regular regimen of daily inhaled corticosteroids (ICS).

According to a report published by the World Allergy Organization Journal in October 2023, the overprescription of short-acting beta-2 agonists among asthma patients suggests a considerable dependency on these medications for immediate symptom relief. This pattern is linked to unfavorable clinical outcomes, with 26.7% of patients receiving at least three canisters of short-acting beta-2 agonists over the past year, correlating with more severe asthma and frequent exacerbations.

The rising number of short-acting beta-2 agonist products used in hospitals, clinical settings, and pharmacies is expected to grow significantly during the forecast period. As more hospitals and clinics adopt these products, the segment will likely experience a considerable growth surge over the coming years. For instance, in January 2024, AstraZeneca launched AIRSUPRA (albuterol/budesonide) in the United States. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of asthma symptoms and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older. Airsupra contains a short-acting beta2-agonist to help relax the smooth muscles of the airways and an inhaled corticosteroid (ICS) to help decrease lung inflammation. Airsupra was approved based on the results from two Phase III trials: MANDALA and DENALI. In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma. In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.

In May 2022, Teva Pharmaceuticals USA Inc., a US affiliate of Teva Pharmaceutical Industries Ltd, published new findings at the 2022 American Thoracic Society (ATS) 2022 Annual Meeting for short-acting beta-2 agonist use established by independent expert consensus to objective patient data from ProAir Digihaler (albuterol sulfate) Inhalation Powder. Expanded savings programs, new medication launches, FDA approvals, and published clinical findings contribute to greater accessibility and adoption of short-acting beta-2 agonists, driving the growth of this market.

The growing market for short-acting beta-2 agonists is driven by factors such as increasing asthma prevalence, over-reliance on these medications, cost-effectiveness, combination therapy trends, and recent product launches and approvals, enhancing accessibility and market adoption. Source: https://www.mordorintelligence.com/industry-reports/asthma-drugs-market

Medication Insights

The quick relief medications segment held the largest share of the asthma drugs market in 2023. Quick relief medications, such as short-acting beta-agonists (SABAs) like albuterol, provide rapid relief from asthma symptoms such as wheezing, chest tightness, and shortness of breath. Their fast-acting nature makes them essential for managing acute asthma attacks. Quick relief medications are often recommended as the first-line treatment for acute asthma symptoms and exacerbations. They are the go-to medications during asthma attacks to provide immediate relief and prevent worsening of symptoms.

Mode of Administration Insights

The inhalers segment held the largest share of the asthma drugs market in 2023 and the segment is observed to sustain the position throughout the forecast period. Inhalers are compact, portable, and easy to use, making them convenient for asthma patients to carry with them wherever they go. This allows patients to have quick access to their medication whenever they experience symptoms or asthma exacerbations. Inhalers deliver medication directly to the lungs, bypassing the digestive system and minimizing systemic side effects commonly associated with oral medications. This targeted delivery helps to reduce the risk of adverse reactions and improves the safety profile of asthma drugs.

Organization Type Insights

The public segment led the asthma drugs market in 2023. Public organizations are responsible for managing healthcare infrastructure, including hospitals, clinics, and public health programs. They ensure the availability and accessibility of asthma drugs to patients through government-funded healthcare services and distribution networks. Public organizations collaborate with pharmaceutical companies, academic institutions, and research organizations to conduct clinical trials, advance scientific research, and develop innovative asthma treatments. These collaborative efforts drive drug discovery and development in the asthma therapeutics market.

Application Insights

The adults segment dominated the asthma drugs market in 2023. Asthma is a chronic respiratory condition that often persists into adulthood. The prevalence of asthma tends to be higher among adults compared to children, leading to a larger patient population in the adult segment. As the global population ages, the proportion of adults with asthma is increasing. Older adults may develop asthma later in life or have existing asthma that requires ongoing management with medication.

Regional Insights

The U.S. asthma drugs market size was valued at USD 8.95 billion in 2023 and is projected to surpass around USD 14.75 billion by 2033, registering a CAGR of 5.12% over the forecast period of 2024 to 2033. 

The research report deals with the industry prospects of asthma drugs products around regions including Europe, North America, Latin America, Asia-Pacific, and Middle East and Africa. Asthma Drugs market is taken by North America owing to increasing numbers of patients suffering from the asthma diseases, advanced healthcare infrastructure, favorable government policies, and growing ageing population U.S. of the North America. Addition to this, presence of leading players in the region along with strategies that are implemented by the major players in the countries of North America is expected to witness substantial growth in the target industry in the near future. Asia Pacific is likely to list the noteworthy CAGR, on account of growth in the demand for the asthma drugs in emerging economies owing growing prevalence. Also, most of the key players operating in the industry are investing heavily in order to get the competitive edge in the asthma drugs market in Asia Pacific. Further, the Latin America as well as Middle East and Africa regions will likely to register moderate growth in the coming.

Asthma Drugs Market Top Key Companies:

• GlaxoSmithKline
• Pfizer
• Vectura Group
• Boehringer Ingelheim
• Roche
• Novartis
• Merck
• AstraZeneca

Teva PharmaceuticalAsthma Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asthma Drugs market.

By Medication

• Quick Relief Medications
• Long-term Control Medications
• Others

By Mode of Administration

• Tablets and Capsules
• Liquids
• Inhalers
• Injections

By Organization Type

• Public
• Private

By Application

• Pediatric
• Adults
• Adolescent

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)